logo-loader

The Hydroponics Company’s appointment will underpin roll-out of Endoca medicinal cannabis products

Published: 13:58 26 Jun 2018 AEST

Medicinal cannabis oil product
Endoca medicinal cannabis products are to be rolled out in Australia

The Hydroponics Company Ltd’s (ASX:THC) appointment of a product and regulatory affairs manager will underpin the roll-out of Endoca’s medicinal cannabis products in Australia.

Katy Williams Day will serve in this role for THC Pharma, a wholly-owned subsidiary of THC.

She fills an essential role in THC as the company begins the landing and distribution of its first medicinal cannabis products into the Australian market from European-based Endoca.

READ: The Hydroponics Company welcomes Canadian bill to legalise recreational cannabis

THC’s chairman Steven Xu said: “We are very pleased to welcome Katy to THC Pharma as a central part of our strategy to introduce Endoca’s products into the Australian market. “Katy’s crossover experience in regulatory affairs and the challenges of new product introduction is exceptional.

“This highly suited Endoca and THC providing medicinal cannabis solutions to patients and their doctors in the near term.”

20 years of experience

Williams Day is qualified as a Master of Pharmacy with more than 20 years of experience in the regulatory, market, quality and clinical development of pharmaceutical products.

Her career includes roles as head of medical affairs, head of regulatory & scientific affairs, director of regulatory affairs and quality.

These have been with organisations including Merck Serono, Phebra, Sandoz, Pfizer and Genzyme.

READ: The Hydroponics Company growing vertically integrated business in medicinal cannabis industry

She is experienced in patient advocacy approaches critical to medicinal cannabis product adoption and maintains active engagement in MS Angels, Rare Voices, Red Cross and other patient support organisations.

Overseeing compliance and regulatory matters

Williams Day will have a lead role in the introduction of Endoca products into the Australian market, as well as overseeing compliance and regulatory matters across THC Pharma operations.

She will also leverage her extensive experience with TGA and international regulatory body submissions to progress THC Pharma’s new product range.

This will come as manufacturing via THC Pharma’s recently acquired pharmaceutical manufacturing facility comes online.

The initial shipment of medicinal cannabis oils from Endoca will be accessible to patients and healthcare professionals in Australia through the MCMP.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 35 minutes ago